On July 31, Halo Pharmaceutical completed its acquisition of Teva‘s Mirabel site in Montreal, Quebec. The transaction had been expected to close by June, but labor negotiations extended the time frame. The site, which Teva gained in its acquisition of Ratiopharm, adds non-sterile creams and ointments and high volume liquids capabilities to Halo’s dosage form portfolio. The facility also provides immediate access to supply clients’ products into the European market. Halo will m...